ExoASO-STAT6 is under clinical development by Codiak BioSciences and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ExoASO-STAT6’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ExoASO-STAT6 overview

exoASO-STAT6 is under development for the treatment of colon cancer, hepatocellular cancer (HCC), gastric cancer, colorectal cancer, pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), ovarian cancer, lung adenocarcinoma, uveal melanoma, glioma, thyroid cancer and fibrosis. It is administered through intravenous route. It acts by targeting signal transducer and activator of transcription 6 (STAT6). The drug candidate is antisense oligonucleotide loaded exosomes being developed based on engEx Platform that can selectively deliver antisense oligonucleotides to M2 macrophages.

Codiak BioSciences overview

Codiak BioSciences is an exosome therapeutics company. The company focuses on the development of proprietary pipeline of targeted medicines for diseases with unmet medical needs. Its engEx platform capitalizes on exosomes, which are nanometer-sized membrane sacs that delivers proteins, lipids, nucleic acids, and small molecules to various cell types. Codiak BioSciences latest pipeline products includes exoSTING, exoIL-12, exoASO-STAT6, oncogene targets, exoASO-NLRP3, gene targets, exoVACC and exoASO-NRAS. The company also has rights to a novel investigational drug candidate for the treatment of pancreatic cancer, from The University of Texas, MD Anderson Cancer Center. Codiak BioSciences is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of ExoASO-STAT6’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.